开云app官网登录入口网页版-官方正版

#临床数据#

91篇内容 | 2138人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2016768, encodeId=8eb72016e6886, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=君实生物口服抗新冠病毒药物VV116公布3项I期临床数据, objectType=article, longId=301010, objectId=cbcc301010a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbcc301010a0, replyNumber=0, likeNumber=87, createdTime=2022-08-18, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbcc301010a0, moduleTitle=君实生物口服抗新冠病毒药物VV116公布3项I期临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cbcc301010a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016771, encodeId=ef6d2016e710e, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=一次注射，长期有效，诺奖团队开发的LNP递送的体内CRISPR疗法最新临床数据给力, objectType=article, longId=730550, objectId=26a7e305503e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26a7e305503e, replyNumber=0, likeNumber=78, createdTime=2023-04-28, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26a7e305503e, moduleTitle=一次注射，长期有效，诺奖团队开发的LNP递送的体内CRISPR疗法最新临床数据给力, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=26a7e305503e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016772, encodeId=fd982016e72aa, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Blood：CAR T细胞治疗大B细胞淋巴瘤的真实临床数据分析, objectType=article, longId=736335, objectId=0832e3633554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0832e3633554, replyNumber=0, likeNumber=142, createdTime=2022-10-11, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0832e3633554, moduleTitle=Blood：CAR T细胞治疗大B细胞淋巴瘤的真实临床数据分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0832e3633554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016765, encodeId=e4b92016e65c6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Liver Cancer：卡博替尼治疗不可切除的肝癌的真实临床数据, objectType=article, longId=216557, objectId=d63121655e33, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d63121655e33, replyNumber=0, likeNumber=88, createdTime=2022-07-29, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d63121655e33, moduleTitle=Liver Cancer：卡博替尼治疗不可切除的肝癌的真实临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d63121655e33)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016770, encodeId=7b962016e703a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Cell Metabolism：上海药物所柳红/黄河团队发布新型降血脂药物1期临床数据, objectType=article, longId=724365, objectId=e020e2436566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e020e2436566, replyNumber=0, likeNumber=67, createdTime=2023-01-30, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e020e2436566, moduleTitle=Cell Metabolism：上海药物所柳红/黄河团队发布新型降血脂药物1期临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e020e2436566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016769, encodeId=ec312016e6908, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=npj Parkinsons Dis：整合英国400万临床数据，帕金森的发病率有何特点？, objectType=article, longId=302223, objectId=6f3a3022238b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f3a3022238b, replyNumber=0, likeNumber=70, createdTime=2022-06-11, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f3a3022238b, moduleTitle=npj Parkinsons Dis：整合英国400万临床数据，帕金森的发病率有何特点？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6f3a3022238b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016766, encodeId=8cb42016e6639, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据, objectType=article, longId=216690, objectId=9b99216690e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b99216690e2, replyNumber=0, likeNumber=61, createdTime=2021-10-31, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b99216690e2, moduleTitle=ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9b99216690e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016763, encodeId=34362016e633a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, objectType=article, longId=214858, objectId=0b4121485899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4121485899, replyNumber=0, likeNumber=75, createdTime=2022-06-18, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4121485899, moduleTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0b4121485899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016759, encodeId=91a02016e59fc, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据, objectType=article, longId=209638, objectId=e44b2096389c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44b2096389c, replyNumber=0, likeNumber=83, createdTime=2022-03-11, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44b2096389c, moduleTitle=RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e44b2096389c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016764, encodeId=58a72016e64a9, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=没有临床数据的如何做临床研究，有没有推荐的数据库？, objectType=article, longId=215609, objectId=edd021560992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd021560992, replyNumber=0, likeNumber=74, createdTime=2022-05-03, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd021560992, moduleTitle=没有临床数据的如何做临床研究，有没有推荐的数据库？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=edd021560992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016762, encodeId=af522016e6220, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, objectType=article, longId=212430, objectId=207d212430a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=207d212430a0, replyNumber=0, likeNumber=102, createdTime=2022-01-25, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=207d212430a0, moduleTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=207d212430a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016755, encodeId=ecad2016e5540, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=SCI TRANS MED：临床数据显示，脑部AAV疗法拯救婴儿致命遗传疾病, objectType=article, longId=204128, objectId=70122041280e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70122041280e, replyNumber=0, likeNumber=89, createdTime=2021-04-07, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70122041280e, moduleTitle=SCI TRANS MED：临床数据显示，脑部AAV疗法拯救婴儿致命遗传疾病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=70122041280e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016761, encodeId=c2812016e61ca, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=ASCO 2021：荣昌生物ADC新药维迪西妥单抗再次亮相大会，展示重磅临床数据！, objectType=article, longId=212341, objectId=7b272123415c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b272123415c, replyNumber=0, likeNumber=74, createdTime=2022-01-10, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b272123415c, moduleTitle=ASCO 2021：荣昌生物ADC新药维迪西妥单抗再次亮相大会，展示重磅临床数据！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7b272123415c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016767, encodeId=1e892016e6720, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=精鼎医药任命前GSK高管Stephen Pyke，为临床数据和数字化服务能力加码, objectType=article, longId=209841, objectId=90a220984160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90a220984160, replyNumber=0, likeNumber=138, createdTime=2021-10-29, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90a220984160, moduleTitle=精鼎医药任命前GSK高管Stephen Pyke，为临床数据和数字化服务能力加码, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=90a220984160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016760, encodeId=5d392016e60e4, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=临床数据显示，Noxopharm的Veyonda®或可预防细胞因子风暴, objectType=article, longId=210640, objectId=47c62106408e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47c62106408e, replyNumber=0, likeNumber=65, createdTime=2022-03-15, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47c62106408e, moduleTitle=临床数据显示，Noxopharm的Veyonda®或可预防细胞因子风暴, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=47c62106408e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016752, encodeId=5f552016e52f3, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代, objectType=article, longId=200929, objectId=978320092943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978320092943, replyNumber=0, likeNumber=79, createdTime=2020-10-20, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978320092943, moduleTitle=Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=978320092943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016751, encodeId=bd682016e515c, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, objectType=article, longId=200219, objectId=a20d20021917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a20d20021917, replyNumber=0, likeNumber=63, createdTime=2020-10-01, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a20d20021917, moduleTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a20d20021917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016754, encodeId=954c2016e5479, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据, objectType=article, longId=203497, objectId=c7a020349eb3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a020349eb3, replyNumber=0, likeNumber=72, createdTime=2021-02-15, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a020349eb3, moduleTitle=Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c7a020349eb3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016745, encodeId=621c2016e45d6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, objectType=article, longId=193204, objectId=9f0e19320472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0e19320472, replyNumber=0, likeNumber=109, createdTime=2021-01-20, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0e19320472, moduleTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9f0e19320472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016746, encodeId=c13c2016e460d, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=EAACI 2020：长期临床数据证实Berotralstat可稳定持久地减少遗传性血管性水肿患者的发作, objectType=article, longId=195487, objectId=d55819548e54, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55819548e54, replyNumber=0, likeNumber=69, createdTime=2020-12-12, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55819548e54, moduleTitle=EAACI 2020：长期临床数据证实Berotralstat可稳定持久地减少遗传性血管性水肿患者的发作, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d55819548e54)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

临床数据

2020-05-29

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

君实生物口服抗新冠病毒药物VV116公布3项I期临床数据

2022-08-18

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

一次注射，长期有效，诺奖团队开发的LNP递送的体内CRISPR疗法最新临床数据给力

2023-04-28

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Blood：CAR T细胞治疗大B细胞淋巴瘤的真实临床数据分析

2022-10-11

柳叶一刀 (审核中...)

前往app查看评论内容

#临床数据#

Liver Cancer：卡博替尼治疗不可切除的肝癌的真实临床数据

2022-07-29

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Cell Metabolism：上海药物所柳红/黄河团队发布新型降血脂药物1期临床数据

2023-01-30

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

npj Parkinsons Dis：整合英国400万临床数据，帕金森的发病率有何特点？

2022-06-11

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

ESMO Open：免疫检查点抑制剂相关的心血管不良事件的真实临床数据

2021-10-31

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法

2022-06-18

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据

2022-03-11

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

没有临床数据的如何做临床研究，有没有推荐的数据库？

2022-05-03

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人

2022-01-25

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

SCI TRANS MED：临床数据显示，脑部AAV疗法拯救婴儿致命遗传疾病

2021-04-07

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

ASCO 2021：荣昌生物ADC新药维迪西妥单抗再次亮相大会，展示重磅临床数据！

2022-01-10

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

精鼎医药任命前GSK高管Stephen Pyke，为临床数据和数字化服务能力加码

2021-10-29

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

临床数据显示，Noxopharm的Veyonda®或可预防细胞因子风暴

2022-03-15

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代

2020-10-20

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人

2020-10-01

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据

2021-02-15

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

瑞德西韦治疗重症住院COVID-19患者III期临床数据公开

2021-01-20

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

EAACI 2020：长期临床数据证实Berotralstat可稳定持久地减少遗传性血管性水肿患者的发作

2020-12-12

科室
- - 订阅+
  - 更多科室
工具
服务